A record of what CA Rudramurthy BV said publicly, with the source. Not advice.
Pending — not yet graded
“Recommends buying Biocon at current market price, targeting an initial level of 400, with a stop loss at 365. This call is based on the strong performance of the pharma sector and Biocon itself.”
CA Rudramurthy BV’s track record (trackable calls only): 33 graded calls · 95% CI 27–59%
BioconBullishCalled 04 Jul 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.